Sales & Marketing

Multi-channel marketing manager Adi Borovick discusses the implications of compliance for marketers in a world where new technologies being created every day.

In its 11th annual feature, Pharm Exec breaks a bit from the norm, to instead profile five products that are shining the spotlight on five critical and highly debated aspects of healthcare and R&D at the moment.

Experts say knowing how to lead in uncertain times and being open to change is just as important as a degree.

With this year marking our 11th installment, we look back on Pharm Exec's first 10 Brands of the Year-why they were chosen and the challenges, changes, and successes since.

The absence of pharma brands on social media creates a significant void of reputable healthcare information to aid patients, writes Dawn Lacallade.

Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.

New DTC campaign for its vaccine Zostavax uses a more serious, personal messaging approach-as pharmas look to close the conversation gaps between patients and healthcare providers.

Charles Benaiah, CEO of New York's watzan, tells Pharm Exec that the key to effective social media marketing is personalization.

A review of some of the sales strategy insights on offer at last month’s eyeforpharma Barcelona event.

In-market experimentation is the best way to address the challenge of pitching brand leaders on new ways to reach their target population through digital and other non-personal channels, write Scott Beauchamp and Michael Calamari.

Stan Bernard outlines the seven ways for pharmas to ensure successful execution of action steps following brand ‘war games’.

Many big pharma companies have been wary of social media. But if you truly want to be customer centric you do need to be in dialogue with your customers - and social media can allow that, writes Will Simpson.

What many in our industry may overlook as they try to identify some new trend are the changes that move below our feet. And they have the potential to disrupt even the most thoughtful marketing plans, writes Al Topin.

In the brave new world of personalized medicine, there are concerns that the one-drug-fits-all mass-marketing approach of the past won’t work, writes Peter Houston.

It's time to take advantage of a nascent technology embrace taking hold among market insights professionals, writes Janet Kolsoff.

Novartis and Bristol-Myers Squibb were among the companies honored with Prix Galien Foundation “Discovery of the Decade” Awards in New York last week.

A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.

Answer 12 key questions to determine if your brand team is leveraging today’s winning competitive strategies and actions.

It’s safe to say content marketing is here to stay, writes Peter Houston. So what is pharma doing with it?

Increasingly, media and marketing companies are looking to online video to rescue shrinking advertising rates and capture coveted social traffic. Peter Houston reports.

Gary Kaplan offers surveying tips to help identify both tactical and strategic initiatives required for a true key performance indicator.

Patients are buried in content, so it must to grab a share of the narrow bandwidths that they possess, writes Casey McDonald

Last month Microsoft bought LinkedIn. What does this mean for pharm execs using the platform? Peter Houston reports.

A new educational and potential prognosis tool for the treatment of multiple sclerosis shows how an accessible, easy-to-see visualization of disease state can serve as the threshold for fresh clinical insight-all geared to the individual patient.

Is Snapchat just for the kids, or should pharma marketers be taking it seriously as a media platform? Peter Houston takes a look.

Pharm Exec’s 10th annual Brand of the Year is Bristol-Myers Squibb’s Opdivo, which has raced into the lead position in the treatment-shifting immuno-oncology space behind launches in three key cancers-melanoma, lung, and renal.